Office of Continuing Medical Education, David Geffen School of Medicine at UCLA presents

**MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:**
A Paradigm Shift in Detection, Grading, Staging, Reporting, Biopsy and Treatment

**Friday - Saturday**
**September 9-10, 2016**

**UCLA Meyer & Renee Luskin Conference Center**
UCLA Campus
Los Angeles, California
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:
A Paradigm Shift in Detection, Grading, Staging, Reporting, Biopsy and Treatment

Course Description:
Prostate cancer is the second most common solid organ malignancy diagnosed in men. Unlike other solid organ malignancies, the challenge in prostate cancer is to confidently identify men with moderate and high grade cancers who would most benefit from aggressive therapy. Uniquely among solid organ cancers, imaging has not been a traditional part of the workup of prostate cancer, which has relied instead on transrectal US-guided template biopsy. MR imaging has emerged as the best imaging modality to detect, grade and stage prostate cancer, especially with the introduction of PI-RADS v2. This unique one-and-a-half-day course will provide a comprehensive overview of the utility of multiparametric MR imaging for prostate cancer diagnosis. We will discuss all relevant MR imaging parameters for prostate cancer (T2, perfusion, diffusion and spectroscopy) as well as new standardized MR reporting algorithms for prostate cancer. In conjunction with the UCLA Departments of Urology, Pathology, Nuclear Medicine and Radiation Oncology and other world renowned speakers, we will review application of MR imaging in surgical planning for robotic prostatectomy, prostate biopsy planning, active surveillance and radiation planning. We will also discuss state-of-the-art MR targeted biopsy, focal therapy and emerging biomarkers.

Target Audience:
Radiologists, urologists, radiation oncologists and family practitioners interested in understanding prostate MR imaging and its applications to active surveillance, biopsy planning and acquisition, surgical planning and radiation planning.

Course Objectives:
At the conclusion of this course, participants should be better able to:
• Describe the use of the multiparametric MRI and post processing for state-of-the-art imaging of prostate cancer
• Recognize the utility of multiparametric MRI for active surveillance, biopsy planning, prostatectomy, and radiation therapy planning
• Understand standardized reporting – PI-RADS v2
• Utilize MRI-based targets for prostate cancer biopsy and therapy
• Identify imaging and genomic biomarkers for prostate cancer prognosis

Accreditation:
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approved by the ASRT for Category A+ continuing education credit.

Disclosure Statement:
The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy now mandates that the sponsor adequately manage all identified potential conflicts of interest prior to the program. We, at UCLA, fully endorse the letter and spirit of these concepts.
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:
A Paradigm Shift in Detection, Grading, Staging, Reporting, Biopsy and Treatment

General Information:
Friday - Saturday
September 9-10, 2016

Registration Fees:
MD Early bird (by July 31, 2016) $300
MD (beginning August 1, 2016) $325
Fellows/Residents/Techs $200

Program Location:
UCLA Meyer & Renee Luskin Conference Center
425 Westwood Plaza
Los Angeles, CA 90095
855-522-8252
www.luskinconferencecenter.ucla.edu

Luskin Conference Center
The Luskin Conference Center features 254 beautifully-appointed guest rooms, many with sweeping views of the stunning campus architecture and beautifully landscaped grounds. The gracious guest experience at the Luskin Conference Center is further enhanced by a full-service restaurant and lounge, on-site professional catering services, well-equipped fitness center, concierge service, business center, and free Wi-Fi throughout the property.

UCLA has arranged a room block at the Luskin Conference Center for our guests. A room rate of $225.00 will be offered (tax exempt). To reserve a room, please contact the Luskin Conference Center after June 1st and indicate you will be attending the UCLA Prostate MRI program. Once the room block is filled, room rates will be subject to availability.

Course Refunds: Cancellations must be received in writing by Friday, August 12, 2016 and will be subject to a $50 processing fee. No refunds will be granted after the cutoff date. If, for any reason, the course must be canceled, discontinued, or rescheduled by the Office of Continuing Medical Education, a full refund will be provided.

Directions and Parking:
From the 405 freeway, exit Wilshire Blvd., east toward Westwood. Turn left on Westwood Blvd., travel past Charles E. Young Dr. South and turn left on Structure 8 driveway. Drive up the ramp to the rooftop level to park. Parking attendants will be selling permits from 6:30 AM - 8:30 AM each day. If you arrive outside of this time frame, please visit the parking kiosk on Westwood Plaza to pay for your parking permit. Participants are responsible for their own parking charges at a rate of $12 per vehicle. The Luskin conference center is located at Westwood Plaza and Strathmore Place.

Additional Information: If you have any questions, please contact the UCLA Office of Continuing Medical Education at (310) 794-2620 or visit our website at www.cme.ucla.edu.

Faculty

Course Director
Steven S. Raman, MD
Professor of Radiology, Urology and Surgery

David Geffen School of Medicine Faculty
Johannes Czernin, MD
Professor of Molecular and Medical Pharmacology
Dieter Enzmann, MD
Professor of Radiology
Leo G. Rigler Chair, Department of Radiology
Isla Garraway, MD
Assistant Professor of Urology
Mitchell Kamrava, MD
Assistant Professor of Radiation Oncology
Teresa Kyles
Assistant Director
Patient Communication Center Financial Services

David S. K. Lu, MD
Professor of Radiology and Surgery

Daniel J. Margolis, MD
Associate Professor of Radiology

Leonard Marks, MD
Professor of Urology

Justin McWilliams, MD
Assistant Professor of Radiology

Glenn Nyborg
MR Technologist
Department of Radiology

Robert Reiter, MD
Professor of Urology
Director of UCLA Prostate SPORE

Nelly Tan, MD
Clinical Instructor in Radiology

Albert Thomas, PhD
Professor of Radiology

Guest Faculty
Hashim U. Ahmed, PhD, BM, BCh
Honorary Consultant Urological Surgeon, UCLH
Director, Prostate Clinical & Research Programme

Duke Bahn, MD
Diagnostic Radiology
Medical Director, Prostate Institute of America

Jiaoti Huang, MD, PhD
Chairman Department of Pathology,
Duke University School of Medicine

Laurence Klotz, MD, FRCS(C)
Professor of Surgery
University of Toronto
## PROGRAM

### DAY 1 - Friday, September 9th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Welcome and Introduction – Basics of Prostate MR Imaging</td>
<td>Steven S. Raman, MD</td>
</tr>
<tr>
<td>8:20</td>
<td>T2/Anatomy</td>
<td>Daniel J. Margolis, MD</td>
</tr>
<tr>
<td>8:35</td>
<td>Diffusion &amp; Perfusion</td>
<td>Daniel J. Margolis, MD</td>
</tr>
<tr>
<td>8:50</td>
<td>MR Spectroscopy</td>
<td>Albert Thomas, PhD</td>
</tr>
<tr>
<td>9:00</td>
<td><strong>Case 1:</strong> Active Surveillance</td>
<td>Steven S. Raman, MD</td>
</tr>
<tr>
<td>9:05</td>
<td>Active Surveillance &amp; MRI</td>
<td>Laurence Klotz, MD</td>
</tr>
<tr>
<td>9:30</td>
<td>Active Surveillance &amp; Targeted Fusion Biopsy</td>
<td>Leonard Marks, MD</td>
</tr>
<tr>
<td>10:00</td>
<td>MRI-Guided Fusion Biopsy</td>
<td>David S. K. Lu, MD</td>
</tr>
<tr>
<td>10:15</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td><strong>Case 2:</strong> Surgical Planning</td>
<td>Steven S. Raman, MD</td>
</tr>
<tr>
<td>10:50</td>
<td>Indications for Prostate MRI</td>
<td>Daniel J. Margolis, MD</td>
</tr>
<tr>
<td>11:00</td>
<td>Surgical Planning with Prostate MRI</td>
<td>Robert Reiter, MD</td>
</tr>
<tr>
<td>11:30</td>
<td>Prostate Pathology</td>
<td>Jiaoti Huang, MD, PhD</td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td>Pro Focal Therapy</td>
<td>Hashim U. Ahmed, PhD, BM, BCh</td>
</tr>
<tr>
<td>2:00</td>
<td>Con Focal Therapy</td>
<td>Robert Reiter, MD</td>
</tr>
<tr>
<td>2:15</td>
<td>Prostate Cryoablation</td>
<td>Duke Bahn, MD</td>
</tr>
<tr>
<td>2:30</td>
<td>Prostate High Intensity Focused Ultrasound</td>
<td>Hashim U. Ahmed, PhD, BM, BCh</td>
</tr>
<tr>
<td>2:45</td>
<td>Emerging Ablative Therapies</td>
<td>Leonard Marks, MD</td>
</tr>
<tr>
<td>3:00</td>
<td>Prostate Artery Embolization</td>
<td>Justin McWilliams, MD</td>
</tr>
<tr>
<td>3:15</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>3:45</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

### DAY 2 - Saturday, September 10th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>The Radiogenomic Revolution</td>
<td>Dieter Enzmann, MD</td>
</tr>
<tr>
<td>8:10</td>
<td>Utility of Prostate Biomarkers</td>
<td>Isla Garraway, MD</td>
</tr>
<tr>
<td>8:40</td>
<td>PI-RADS v2 as an Imaging Biomarker</td>
<td>Daniel J. Margolis, MD</td>
</tr>
<tr>
<td>8:50</td>
<td>Prostate Cancer RadPath Imaging Atlas</td>
<td>Daniel J. Margolis, MD</td>
</tr>
<tr>
<td>9:00</td>
<td>Building a Predictive Model</td>
<td>Nelly Tan, MD</td>
</tr>
<tr>
<td>9:15</td>
<td>Imaging as a Predictive Biomarker</td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Break (Discussion Continues)</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>Case 3:</strong> MRI in Radiation Therapy and MRI in Focal Therapy</td>
<td>Steven S. Raman, MD</td>
</tr>
<tr>
<td>10:35</td>
<td>MRI for Radiation Therapy &amp; Focal Therapy</td>
<td>Daniel J. Margolis, MD</td>
</tr>
<tr>
<td>10:45</td>
<td>MRI in XRT</td>
<td>Mitchell Kamrava, MD</td>
</tr>
<tr>
<td>11:15</td>
<td>Nuclear Medicine for Prostate Cancer</td>
<td>Johannes Czernin, MD</td>
</tr>
<tr>
<td>11:45</td>
<td>Imaging for Biochemical Recurrence</td>
<td>Daniel Margolis, MD</td>
</tr>
<tr>
<td>12:00</td>
<td>Patient Experience</td>
<td>Glenn Nyborg</td>
</tr>
<tr>
<td>12:15</td>
<td>Insurance and Billing</td>
<td>Teresa Kyles</td>
</tr>
<tr>
<td>12:30</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Friday, September 9th (Non-CME Accredited Session)**

3:45-5:00  **Complimentary Hands-on Session**

The hands-on session will provide a valuable learning opportunity, though no CME credit will be issued for this portion of the program. The hands-on session is complimentary and will give participants an opportunity to work with trainers that will demonstrate the use of each system (i.e. cryoablation, targeted biopsy, HiFU, image analysis). Attendees will also be able to learn from each supporting vendor on each of the current platforms available.
# MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management

<table>
<thead>
<tr>
<th>Course Title and Number</th>
<th>Registration Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management</td>
<td>M167-16</td>
</tr>
<tr>
<td>MD Early bird (by July 31, 2016)</td>
<td>$300</td>
</tr>
<tr>
<td>MD (beginning August 1, 2016)</td>
<td>$325</td>
</tr>
<tr>
<td>Fellows/Residents/Techs/Nurses</td>
<td>$200</td>
</tr>
</tbody>
</table>

**Enrollment:**

**Online** – Go to www.cme.ucla.edu/courses, click on **MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management**, and click the registration button. You may use your MasterCard, VISA, American Express or Discover card to register online.

**By Mail** – Use the form attached. Mail to:
UCLA Office of Continuing Medical Education
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management
10920 Wilshire Blvd., Ste. 1060
Los Angeles, CA 90024-6512

**By Fax** – Send the completed enrollment form with credit card information and authorizing signature. FAX 310-794-2624.

**By Phone** – Use your MasterCard, VISA, American Express or Discover Card. Call the Office of CME at 310-794-2620.

Please visit our website for other UCLA CME offerings: www.cme.ucla.edu

Early registration is recommended as space is limited!
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:
A Paradigm Shift in Detection, Grading, Staging, Reporting, Biopsy and Treatment

Friday - Saturday
September 9-10, 2016
www.cme.ucla.edu/courses